2015 BPD Header
2013 Archived Content

 

Short Course 7: TRANSIENT PROTEIN PRODUCTION
IN MAMMALIAN CELLS

Thursday, August 22, 2013 | 6:00 - 9:00 pm

 

Detailed Agenda: 

 

6:00 Opening Remarks   

Richard Altman, MS, Research Scientist, Alexion Pharmaceuticals

6:05 Fundamental Elements of Transient Protein Production   

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, SAIC-Frederick, Inc.

  1. Expression Vectors

 

6:40 Fundamental Elements of Transient Protein Production   

Henry C. Chiou, Ph.D., Senior Manager, Molecular Biology, Life Technologies Corporation

  1. Cell lines
  2. Media and cell culture
  3. Transfection reagents and protocols
  4. Strategies for maximizing yields

 

7:15 Dinner Break  

 

7:20 Implementing Transient Protein Production   

Richard Altman, MS, Research Scientist, Alexion Pharmaceuticals

  1. What is your goal/objective for transient protein expression?
  2. What equipment and space is required?
  3. Case study

7:55 Implementing Transient Protein Production   

Krista Johnson, MSc, Research Scientist, Alexion Pharmaceuticals

  1. Tools and strategies for purification of transiently expressed proteins
  2. Methods of evaluation of purified proteins from transient expression

 

8:30 Interactive Discussion  

 

9:00 Close of Transient Protein Production in Mammalian Cells Short Course  

 

 

 Speaker Bios   

 

Richard Altman Richard Altman, MS, Research Scientist, Alexion Pharmaceuticals
Mr. Altman has over 23 years of experience working in the pharmaceutical industry. For the past two years, he has worked in the Molecular Sciences group at Alexion Pharmaceuticals developing antibody and non-antibody biologics. Prior to Alexion, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both high-throughput screening and protein therapeutic efforts. In addition, he has been involved in the generation of transgenic animal models and their characterization. Mr. Altman received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.  

Henry ChiouHenry C. Chiou, Ph.D., Senior Manager, Molecular Biology, Life Technologies Corporation

Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years he has worked as a principal scientist and now in product development and portfolio management for Life Technologies. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, SAIC-Frederick, Inc.  

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at SAIC-Frederick, Inc. The 26 employees in the PEL generate proteins of interest to investigators at the National Cancer Institute and other NIH facilities, and invent and develop new technologies for protein expression and production. Prior to his role as director, Dr. Esposito led the Clone Optimization Group in the PEL for nine years and was responsible for the generation of over 15,000 expression clones, 400 new expression vectors and several technological innovations in protein expression. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.

Krista_JohnsonKrista Johnson, MSc, Research Scientist, Alexion Pharmaceuticals 

Krista Johnson has been in the biotech industry for 20 years, working on all aspects of antibody therapeutic development. She has been purifying and characterizing antibodies and recombinant proteins for in vivo and in vitro use for over 10 years as part of the research and development team at Alexion. She was on the team that discovered and developed Soliris (eculizumab), a first-in-class terminal complement inhibitor. Krista holds a BSc in chemistry and obtained her MSc degree in pharmacology from Dalhousie University in Canada.

 

«Back to Short Courses